Urania Therapeutics is developing a SBDD platform for the generation.

Urania Therapeutics, a spin-off from IGBMC, leverages the long-term work of Marat Yusupov and Gulnara Yusupova on the eukaryotic ribosome to develop new drugs, in particular "readthrough compounds" targeting the voir plus

Urania Therapeutics, a spin-off from IGBMC, leverages the long-term work of Marat Yusupov and Gulnara Yusupova on the eukaryotic ribosome to develop new drugs, in particular "readthrough compounds" targeting the human ribosome for the treatment of genetic diseases when they are caused by nonsense mutations (10-15% of cases). Distinctively from gene therapies, RiboStruct develops a "protein repair therapy" approach, with the hope to cure various diseases with a same set of molecules by acting on a common mechanism. More than 7000 genetic diseases have been described so far, affecting altogether 300 million people worlwide. voir moins